Ann: Permetrex Outperforms Other CBD Topical Products, page-59

You make some good points and - as posted earlier - I'd suggest that yesterday announcements shall be seen not so much for what it 'says' but for what it 'does' (which is why it was commissioned): it gives the board extra leverage in negotiating licencing deal(s) for Permetrex. It does so by giving exposure to Permetrex performance against other topical OTC products containing CBD - which happens to be the only available comparative objects for the study since there are no FDA approved topically applied drugs containing CBD. That is the benchmark against which BTX1503 should have be compared but it just can't be done cause we are 'two and a half years ahead' of the rest....so it was done with OTC products whose claims needs to be discredited -anyhow- as BOT's products make progress along the way. 
On the issue of the dosage of CBD, I think that the trials will work that out. 
You're right, this is 'Marketing', for Permetrex, BTX1503 and the 'story' taking shape.